Project overview Joint Funding
SI-SARS-CoV2 (Immune responses to SARS-CoV-2)
Programs: Overarching Funding Line: strategic initiative Project type: research project Partner site: Essen/Dusseldorf, Freiburg, Heidelberg, Munich Entity: COVID-19, multiple entities Status: completed
SIGN-OC (Signature for Neoadjuvant Chemotherapy in Ovarian Cancer)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Munich, Tubingen Entity: ovarian cancer Status: completed
SIOrgP (DKTK Organoid Platform)
Programs: Overarching Funding Line: strategic initiative Project type: technology platform Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Status: current
SORATRAM (CRAF/MEK inhibition for inactivating BRAF mutations)
Program: MTT Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
Targeting Myc (Therapeutic targeting of Myc)
Program: MTT Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg, Tubingen Entity: multiple entities Status: completed
Translation of molecular based treatment approaches in ALL (Functional modeling of molecular based treatment approaches in relapsed acute lymphoblastic leukemia)
Program: MTT Funding Line: INNOVATION Project type: research project Partner site: Berlin, Frankfurt/Mainz, Munich Entity: blood cancer Status: completed
TRICKY (Tumor heterogeneity impacts immunotherapy)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Essen/Dusseldorf, Heidelberg Entity: skin cancer Status: current
TRUST (Translational program of IT-PD1/NOA-26 study)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Tubingen Entity: multiple entities Status: current
UniCAR NK cells (Chimeric antigen receptor-engineered natural killer cells as a universal cellular therapeutic for adoptive cancer immunotherapy)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg Entity: skin cancer Status: completed